Adia Med, Inc. has announced the full repayment of its unsecured revolving line of credit, a significant financial milestone for the company. The repayment, completed on October 9, 2026, signals a strategic move to enhance its financial position and operational flexibility.
The company, which operates in the medicinal chemicals and botanical products sector, has worked to improve its financial health by discharging this debt. The revolving credit facility, originally established on June 30, 2024, had been increased to a commitment of $1,000,000 to support the company's growth needs, bearing an interest rate of 6% per annum.
According to the filing, Adia Med made two substantial payments to settle the debt: $500,000 on October 7, 2026, followed by $434,970.94 on October 9, 2026. This latter payment included $74,658.94 in accrued interest, with the remainder applied to the principal. In total, the company paid $934,970.94 to fully satisfy its obligations under the credit facility.
The lender of this facility was Larry Powalisz, the Chief Executive Officer of Adia Med. The filing confirms that the lender acknowledged the full payment of the outstanding principal and accrued interest, thereby discharging the facility entirely.
This repayment is expected to have a positive impact on Adia Med's operations, allowing the company to allocate resources more efficiently and potentially pursue new growth opportunities without the burden of debt. The medicinal chemicals and botanical products industry may see this as a sign of financial stability, which could influence competitors and market dynamics.
As of now, it is unclear what specific actions Adia Med will take following this repayment. The company has not disclosed any further plans or upcoming filings related to this development.
For more details, the full text of the Paid-in-Full Acknowledgment can be found in Exhibit 10.1 of the filing.